What is budesonide delayed-release capsules? Is it on the market?

Budesonide delayed-release capsules (trade nameTarpeyo) are an innovative oral delayed-release corticosteroid preparation that has injected new vitality into the treatment field of adult primary immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease prevalent worldwide, characterized by the deposition of immunoglobulin A in the glomeruli, inducing an inflammatory response and gradually leading to renal function decline. This disease has a high risk of progression to end-stage renal disease (ESRD), especially in certain ethnic groups, seriously threatening the quality of life and safety of patients. The pathological mechanism of IgAN is complex, in which galactose-deficient IgA1 (Gd-IgA1) plays a central role. This abnormal form of IgA1 is mainly produced by B cells in the ileal mucosa and is involved in the onset and progression of the disease.

Aiming at this pathological mechanism, budesonide delayed-release capsules have become a new dawn in the field of IgAN treatment with its unique anti-inflammatory and immunomodulatory functions. This drug effectively relieves renal inflammation by regulating the number and activity of mucosal B cells, thereby delaying the progression of renal function decline.

The development of budesonide delayed-release capsules was full of challenges and breakthroughs. In December 2021, it won accelerated approval from the U.S. Food and Drug Administration (FDA) for the first time. This landmark achievement initially confirmed its potential in the treatment of IgAN. After subsequent clinical trials and verification, the drug was fully approved by the FDA in December 2023, becoming the first therapeutic drug proven to significantly slow down the loss of renal function in IgA nephropathy.

However, the use of all drugs is associated with certain risks, and budesonide delayed-release capsules are no exception. Common side effects include hypertension, peripheral edema, muscle twitching, acne, dermatitis, weight gain, dyspnea, facial swelling, indigestion, fatigue and hirsutism. Therefore, when using this drug, doctors need to carefully evaluate the patient's specific condition, weigh the pros and cons, and formulate a targeted treatment plan.

What is gratifying is that budesonide delayed-release capsules have obtained marketing approval in my country and are marketed under the trade name"Budesonide Enteric-Coated Capsules (Nefukang)". This news undoubtedly brings new treatment opportunities for domestic IgAN patients. However, due to factors such as regional differences and market competition, the specific selling price of the drug may differ in different regions. Therefore, it is recommended that patients consult local pharmacies or medical institutions when purchasing to obtain the most accurate price information.

In summary, budesonide delayed-release capsules (Naifukang), as a new type of IgAN treatment drug, its unique mechanism of action and significant clinical efficacy provide patients with a new treatment approach. However, the use of drugs must be done under the guidance of a doctor to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/history/tarpeyo.html